- Research works
- 12 ▲ 68% vs 2018-21
- Citations
- 192 15.4 per fractional work
- Top-10% rate
- 21.7% all institutions 10.0%
- Open access
- 50% world 40%
- International
- 40% world 18%
Not ranked overall: CymaBay Therapeutics (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.
Which fields of science does CymaBay Therapeutics (United States) work in?
In all years, 57% of research at CymaBay Therapeutics (United States) is in Health Sciences, 33% in Life Sciences. Its largest fields are Medicine (55%), Biochemistry, Genetics and Molecular Biology (22%), Pharmacology, Toxicology and Pharmaceutics (8%). It does 1.7× the world's share of Health Sciences.
Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.
Its 4 domains and 11 fields, with their numbers
- Health Sciences756.9%
- Life Sciences433.4%
- Social Sciences15.5%
- Economics, Econometrics and Finance02.7%
- Social Sciences01.9%
- Psychology00.9%
- Physical Sciences14.2%
- Engineering02.7%
- Materials Science01.4%
- Chemistry00.2%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 5.1×. Every wedge is a field page.
All 6 fields, with their numbers
- Biochemistry, Genetics and Molecular Biology5.06×1 works
- Immunology and Microbiology4.33×0 works
- Medicine3.36×3 works
- Pharmacology, Toxicology and Pharmaceutics0.96×0 works
- Engineering0.23×0 works
- Social Sciences0.03×0 works
Who are the top researchers at CymaBay Therapeutics (United States)?
Ranked on the quality score, Charles A. McWherter and Alexandra S. Steinberg lead among researchers whose main affiliation is CymaBay Therapeutics (United States).
- 1
Charles A. McWherter
United States · #721,076 worldwide 2.7k citations · 101 works
- 2
Alexandra S. Steinberg
United States · #1,072,590 worldwide 746 citations · 43 works
Which research topics does CymaBay Therapeutics (United States) publish most on?
By volume in 2022-now: Liver Disease Diagnosis and Treatment, Drug Transport and Resistance Mechanisms, Liver Diseases and Immunity and Peroxisome Proliferator-Activated Receptors.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Liver Disease Diagnosis and Treatment Epidemiology 1 works
- 2 Drug Transport and Resistance Mechanisms Oncology 1 works
- 3 Liver Diseases and Immunity Hepatology 0 works
- 4 Peroxisome Proliferator-Activated Receptors Molecular Biology 0 works
- 5 Cancer Research and Treatments Biotechnology 0 works
- 6 Pediatric Hepatobiliary Diseases and Treatments Surgery 0 works
- 7 Gallbladder and Bile Duct Disorders Pulmonary and Respiratory Medicine 0 works
- 8 Virus-based gene therapy research Genetics 0 works
- 9 Aldose Reductase and Taurine Cell Biology 0 works
- 10 interferon and immune responses Immunology 0 works
How open and international is its research?
Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 40% of research is openly available.
World: 18% is written across borders.
How has CymaBay Therapeutics (United States)'s research output changed?
Output in 2022-2025 was 68% higher than in 2018-2021.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is CymaBay Therapeutics (United States) as a percentage of every work published that year, 0.000018% in 2023.
Fractional works of CymaBay Therapeutics (United States) over all fractional works that year. How the balance of science has shifted.
Other research institutions in Newark
- Membrane Technology & Research (United States)
- KWJ Engineering (United States)
- Depomed (United States)
- SMART Global Holdings (United States)
- Triple Ring Technologies (United States)
- DryScrub (United States)
- Envia Systems (United States)
- BioChain Institute (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.
Discussion
Ask a question or share a note about CymaBay Therapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.